513-P: Associations of Common Mental Health Disorders with Impaired Awareness of Hypoglycaemia in Type 1 Diabetes

Objective: This cross-sectional study aimed to assess the prevalence of mental health disorders and impaired awareness of hypoglycemia (IAH) in type 1 diabetes, as well as examine associations between these and sociodemographic and clinical characteristics. It also assessed the hypothesis that symptoms of common mental health disorders are independently associated with IAH. Methods: Data was collected from patients attending a diabetes outpatient clinic between January 2016 and April 2018 who completed questionnaires as part of routine clinical care. Probable depression (pMDD), probable anxiety (pGAD) and IAH were measured using validated self-report tools. Associations were examined with multiple regression models, adjusting for sociodemographic and clinical characteristics. Results: Data from 950 patients was included in the sample. 93 patients (9.8%) met criteria for pMDD; 89 patients (9.4%) met criteria for pGAD; and 215 (22.6%) patients met criteria for IAH. Only depression was independently associated with IAH after adjustment for covariates when depression and anxiety were included in the same model (OR 3.27 (CI 1.74-6.15)). However, both depression and anxiety were associated with increased odds of IAH and robust to adjustment, when included separately (OR 3.64 (CI 2.19-6.04), and OR 2.46 (CI 1.46-4.14), respectively). Conclusions: The robust independent relationship between symptoms of common mental health disorders, and in particular depression, with IAH demonstrates the need for routine psychological assessment and management in people with type 1 diabetes patients and IAH. This data also provides further support for the inclusion of mental health support strategies alongside the use of technology in hypoglycemia awareness restoration programmes. Disclosure B. Pieri: None. G. Bergin-cartwright: None. M. Hotopf: Research Support; Self; Biogen, Janssen Pharmaceuticals, Inc., Lundbeck, Merck Sharp & Dohme Corp., UCB Japan Co. Ltd. S. Hussain: Speaker’s Bureau; Self; Novo Nordisk.